drug price – Talk Bio

J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025

2 days ago talkbio0Tagged Autoimmune Diseases, Benefit, Biosimilars, drug price, formulary exclusion, Johnson & Johnson, manager, Pharmaceutical Services, Revenue Decline, Stelara, ustekinumab

Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease

FDA Commissioner Makary Proposes Fast-Track Drug Review Vouchers Tied to Lower US Prices, Without Detailing Criteria

1 week ago talkbio0Tagged drug price, fast-track approval, Makary, national priority review vouchers, Parity, pilot program, Prices, United States Food and Drug Administration

FDA; Makary; national priority review vouchers; drug pricing; fast-track approval; price parity; pilot program

Trump Administration Considers Limits on Direct-to-Consumer Drug Advertising

1 month ago talkbio0Tagged Ditiocarb, drug price, executive order, Health Policy, Pharma, pharmaceutical regulation, Transplant Registry Unified Management Program

Trump administration; DTC drug advertising; pharmaceutical regulation; drug pricing; executive order; health policy; pharma marketing

FDA Reinstates Generic Drug Policy Group After April Firings

1 month ago talkbio0Tagged Administrative action, Departure - action, development aspects, drug price, Generic Drugs, layoffs, Office, Policy, reinstatement, Transection (procedure), United States Food and Drug Administration

FDA; generic drugs; policy office; Division of Policy Development; reinstatement; layoffs; drug prices; administrative leave

Trump Taps Dr. Oz as Lead Negotiator for ‘Most Favored Nation’ Drug Pricing Policy

2 months ago talkbio0Tagged Dr., Drug Costs, drug price, Health Policy, Myasthenic Syndromes, Congenital, Nation, ounce, pharmaceutical negotiations, Transplant Registry Unified Management Program

Trump; Dr. Mehmet Oz; Most Favored Nation; drug pricing; CMS; pharmaceutical negotiations; healthcare policy; drug costs

HHS: All Branded Drugs Without Generic or Biosimilar Competition Must Abide by MFN Order Across All Markets

2 months ago talkbio0Tagged biosimilar competition, branded drugs, CHARGE Syndrome, Country, Drug Industry, drug price, executive order, Generic competition, most-favored, Organisation for Economic Co-Operation and Development

most-favored nation pricing; branded drugs; generic competition; biosimilar competition; HHS; executive order; drug pricing; pharmaceutical industry; OECD countries

‘Go ahead and do it’: Top RFK Jr. Deputy Dares Drugmakers Over Threats to Pull Manufacturing Amid Price Pressure

2 months ago talkbio0Tagged Big Pharma, Calley Means, CHARGE Syndrome, Drug Industry, drug price, executive order, HHS, Manufacturing, Prices, RFK Jr., Roche (company), threat

RFK Jr.; drug pricing; Calley Means; HHS; pharmaceutical industry; manufacturing threats; Roche; executive order; price limits; Big Pharma

White House Threatens Most Favored Nation Plan to Lower US Drug Prices, but Many Questions Remain

2 months ago talkbio0Tagged Comparison, Drug Prescriptions, drug price, Favored, global price, Nation, Pharmaceutical Policy, Trump administration, U.S., White House

Most Favored Nation; drug pricing; White House; executive order; prescription drugs; Trump administration; US drug prices; global price comparison; pharmaceutical policy